Glucagon-like peptide-1 (GLP-1) analogs: Recent advances, new possibilities, and therapeutic implications

Journal of Medicinal Chemistry

Volumn 58, Issue 3, 2015, Pages 1020-1037

  Manandhar, Bikash ^a   Ahn, Jung Mo ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ALBIGLUTIDE; CYCLIC AMP; DAVALINTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EFPEGLENATIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUTAMIC ACID; GLYCINE; IMIDAZOLE; ISOLEUCINE; LIRAGLUTIDE; PHENYLALANINE; SEMAGLUTIDE; SERINE; TASPOGLUTIDE; VALINE;

ARTICLE; BIOLOGICAL ACTIVITY; CELL PROLIFERATION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; GLUCOSE METABOLISM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MACROMOLECULE; MOLECULAR IMAGING; NONHUMAN; PANCREAS ISLET BETA CELL; RECEPTOR BINDING; ANIMAL; DIABETES MELLITUS; METABOLISM;

ANIMALS; DIABETES MELLITUS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN-SECRETING CELLS; MOLECULAR IMAGING;

EID: 84922771356     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500810s     Document Type: Article

References (174)

1. Gutniak, M.; Ørkov, C.; Holst, J. J.; Ahrén, B.; Efendić, S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus N. Engl. J. Med. 1992, 326, 1316-1322
2. Holst, J. J.; Gromada, J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans Am. J. Physiol.: Endocrinol. Metabol. 2004, 287, E199-E206
3. MacDonald, P. E.; El-kholy, W.; Riedel, M. J.; Salapatek, A. M. F.; Light, P. E.; Wheeler, M. B. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion Diabetes 2002, 51, S434-S442
4. Brubaker, P. L.; Drucker, D. J. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system Endocrinology 2004, 145, 2653-2659
5. Deacon, C. F. Therapeutic strategies based on glucagon-like peptide 1 Diabetes 2004, 53, 2181-2189
6. Kieffer, T. J.; Habener, J. F. The glucagon-like peptides Endocr. Rev. 1999, 20, 876-913
7. Campos, R. V.; Lee, Y. C.; Drucker, D. J. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse Endocrinology 1994, 134, 2156-2164
8. Bullock, B. P.; Heller, R. S.; Habener, J. F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor Endocrinology 1996, 137, 2968-2978
9. Tornehave, D.; Kristensen, P.; Rømer, J.; Knudsen, L. B.; Heller, R. S. Expression of the GLP-1 receptor in mouse, rat, and human pancreas J. Histochem. Cytochem. 2008, 56, 841-851
10. De Marinis, Y. Z.; Salehi, A.; Ward, C. E.; Zhang, Q.; Abdulkader, F.; Bengtsson, M.; Braha, O.; Braun, M.; Ramracheya, R.; Amisten, S.; Habib, A. M.; Moritoh, Y.; Zhang, E.; Reimann, F.; Rosengren, A. H.; Shibasaki, T.; Gribble, F.; Renström, E.; Seino, S.; Eliasson, L.; Rorsman, P. GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis Cell Metab. 2010, 11, 543-553
11. Bell, G. I.; Santerre, R. F.; Mullenbach, G. T. Hamster preproglucagon contains the sequence of glucagon and two related peptides Nature 1983, 302, 716-718
12. Lund, P. K.; Goodman, R. H.; Dee, P. C.; Habener, J. F. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem Proc. Natl. Acad. Sci. U.S.A. 1982, 79, 345-349
13. Perry, T.; Greig, N. H. The glucagon-like peptides: a double-edged therapeutic sword? Trends Pharmacol. Sci. 2003, 24, 377-383
14. Holst, J. J. The physiology of glucagon-like peptide 1 Physiol. Rev. 2007, 87, 1409-1439
15. Hupe-Sodmann, K.; Göke, R.; Göke, B.; Thole, H. H.; Zimmermann, B.; Voigt, K.; McGregor, G. P. Endoproteolysis of glucagon-like peptide (GLP)-1(7-36) amide by ectopeptidases in RINm5F cells Peptides 1997, 18, 625-632
16. Mentlein, R.; G, B.; Schmidt, W. E. Dipeptidyl peptidase-IV hydrolyzes gastric-inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum Eur. J. Biochem. 1993, 214, 829-835
17. Montrose-Rafizadeh, C.; Yang, H.; Rodgers, B. D.; Beday, A.; Pritchette, L. A.; Eng, J. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor J. Biol. Chem. 1997, 272, 21201-21206
18. Deacon, C. F.; Nauck, M. A.; Toft-Nielsen, M.; Pridal, L.; Willms, B.; Holst, J. J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects Diabetes 1995, 44, 1126-1131
19. Vahl, T. P.; Paty, B. W.; Fuller, B. D.; Prigeon, R. L.; DAlessio, D. A. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans J. Clin. Endocrinol. Metab. 2003, 88, 1772-1779
20. Elahi, D.; Egan, J. M.; Shannon, R. P.; Meneilly, G. S.; Khatri, A.; Habener, J. F.; Andersen, D. K. GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide Obesity 2008, 16, 1501-1509
21. Deacon, C. F.; Plamboeck, A.; Møller, S.; Holst, J. J. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion Am. J. Physiol.: Endocrinol. Metabol. 2002, 282, E873-E879
22. Nikolaidis, L. A.; Elahi, D.; Shen, Y.-T.; Shannon, R. P. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy Am. J. Physiol.: Heart Circ. Physiol. 2005, 289, H2401-H2408
23. Plamboeck, A.; Holst, J.; Carr, R.; Deacon, C. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig Diabetologia 2005, 48, 1882-1890
24. Davidson, M. B.; Bate, G.; Kirkpatrick, P. Fresh from the pipeline: exenatide Nat. Rev. Drug Discovery 2005, 4, 713-714
25. Knudsen, L. B.; Nielsen, P. F.; Huusfeldt, P. O.; Johansen, N. L.; Madsen, K.; Pedersen, F. Z.; Thøgersen, H.; Wilken, M.; Agersø, H. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration J. Med. Chem. 2000, 43, 1664-1669
26. Kim, D.; MacConell, L.; Zhuang, D.; Kothare, P. A.; Trautmann, M.; Fineman, M.; Taylor, K. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes Diabetes Care 2007, 30, 1487-1493
27. Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H.; Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M. E.; Patel, R. A.; Petrov, A.; Scapin, G.; Patel, S. B.; Roy, R. S.; Wu, J. K.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber, A. E. (2 R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3- a ]pyrazin- 7(8 H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 2005, 48, 141-151
28. Gallwitz, B.; Witt, M.; Paetzold, G.; Morys-Wortmann, C.; Zimmermann, B.; Eckart, K.; Folsch, U. R.; Schmidt, W. E. Structure/activity characterization of glucagon-like peptide-1 Eur. J. Biochem. 1994, 225, 1151-1156
29. Adelhorst, K.; Hedegaard, B. B.; Knudsen, L. B.; Kirk, O. Structure-activity studies of glucagon-like peptide-1 J. Biol. Chem. 1994, 269, 6275-6278
30. Hareter, A.; Hoffmann, E.; Bode, H. P.; Goke, B.; Goke, R. The positive charge of the imidazole side chain of histidine7 is crucial for GLP-1 action Endocr. J. 1997, 44, 701-705
31. Gallwitz, B.; Ropeter, T.; Morys-Wortmann, C.; Mentlein, R.; Siegel, E. G.; Schmidt, W. E. GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro Regul. Pept. 2000, 86, 103-111
32. Sarrauste de Menthiere, C.; Chavanieu, A.; Grassy, G.; Dalle, S.; Salazar, G.; Kervran, A.; Pfeiffer, B.; Renard, P.; Delagrange, P.; Manechez, D.; Bakes, D.; Ktorza, A.; Calas, B. Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production Eur. J. Med. Chem. 2004, 39, 473-480
33. Green, B. D.; Mooney, M. H.; Gault, V. A.; Irwin, N.; Bailey, C. J.; Harriott, P.; Greer, B.; OHarte, F. P.; Flatt, P. R. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity J. Endocrinol. 2004, 180, 379-388
34. OHarte, F. P.; Mooney, M. H.; Lawlor, A.; Flatt, P. R. N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo Biochim. Biophys. Acta 2000, 1474, 13-22
35. Youn, Y. S.; Chae, S. Y.; Lee, S.; Jeon, J. E.; Shin, H. G.; Lee, K. C. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: insulinotropic activity, glucose-stabilizing capability, and proteolytic stability Biochem. Pharmacol. 2007, 73, 84-93
36. Burcelin, R.; Dolci, W.; Thorens, B. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1 Metabolism 1999, 48, 252-258
37. Deacon, C. F.; Knudsen, L. B.; Madsen, K.; Wiberg, F. C.; Jacobsen, O.; Holst, J. J. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity Diabetologia 1998, 41, 271-278
38. Xiao, Q.; Giguere, J.; Parisien, M.; Jeng, W.; St-Pierre, S. A.; Brubaker, P. L.; Wheeler, M. B. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo Biochemistry 2001, 40, 2860-2869
39. Green, B. D.; Mooney, M. H.; Gault, V. A.; Irwin, N.; Bailey, C. J.; Harriott, P.; Greer, B.; Flatt, P. R.; OHarte, F. P. Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39) Metabolism 2004, 53, 252-259
40. Green, B. D.; Gault, V. A.; Irwin, N.; Mooney, M. H.; Bailey, C. J.; Harriott, P.; Greer, B.; Flatt, P. R.; OHarte, F. P. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1 Biol. Chem. 2003, 384, 1543-1551
41. Meng, H.; Krishnaji, S. T.; Beinborn, M.; Kumar, K. Influence of selective fluorination on the biological activity and proteolytic stability of glucagon-like peptide-1 J. Med. Chem. 2008, 51, 7303-7307
42. Watanabe, Y.; Kawai, K.; Ohashi, S.; Yokota, C.; Suzuki, S.; Yamashita, K. Structure-activity relationships of glucagon-like peptide-1(7-36)amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells J. Endocrinol. 1994, 140, 45-52
43. Fehmann, H. C.; Goke, B. The insulinotropic gut hormone glucagon like peptide-1. In Frontiers in Diabetes; Belfiore, F., Ed.; Karger: Basel, Switzerland, 1997; Vol. 13, pp 1-99.
44. Miranda, L. P.; Winters, K. A.; Gegg, C. V.; Patel, A.; Aral, J.; Long, J.; Zhang, J.; Diamond, S.; Guido, M.; Stanislaus, S.; Ma, M.; Li, H.; Rose, M. J.; Poppe, L.; Véniant, M. M. Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity J. Med. Chem. 2008, 51, 2758-2765
45. Behnam Azad, B.; Rota, V. A.; Breadner, D.; Dhanvantari, S.; Luyt, L. G. Design, synthesis and in vitro characterization of glucagon-like peptide-1 derivatives for pancreatic beta cell imaging by SPECT Bioorg. Med. Chem. 2010, 18, 1265-1272
46. Green, B. D.; Gault, V. A.; Mooney, M. H.; Irwin, N.; Harriott, P.; Greer, B.; Bailey, C. J.; OHarte, F. P.; Flatt, P. R. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues Biol. Chem. 2004, 385, 169-177
47. Ueda, T.; Tomita, K.; Notsu, Y.; Ito, T.; Fumoto, M.; Takakura, T.; Nagatome, H.; Takimoto, A.; Mihara, S.; Togame, H.; Kawamoto, K.; Iwasaki, T.; Asakura, K.; Oshima, T.; Hanasaki, K.; Nishimura, S.; Kondo, H. Chemoenzymatic synthesis of glycosylated glucagon-like peptide 1: effect of glycosylation on proteolytic resistance and in vivo blood glucose-lowering activity J. Am. Chem. Soc. 2009, 131, 6237-6245
48. Sebokova, E.; Christ, A. D.; Wang, H.; Sewing, S.; Dong, J. Z.; Taylor, J.; Cawthorne, M. A.; Culler, M. D. Taspoglutide, an analog of human glucagon-like peptide-1 with enhanced stability and in vivo potency Endocrinology 2010, 151, 2474-2482
49. Dong, J. Z.; Shen, Y.; Zhang, J.; Tsomaia, N.; Mierke, D. F.; Taylor, J. E. Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes Diabetes Obes. Metab. 2011, 13, 19-25
50. Tomas, E.; Habener, J. F. Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis Trends Endocrinol. Metab. 2010, 21, 59-67
51. Meier, J. J.; Gethmann, A.; Nauck, M. A.; Götze, O.; Schmitz, F.; Deacon, C. F.; Gallwitz, B.; Schmidt, W. E.; Holst, J. J. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans Am. J. Physiol.: Endocrinol. Metabol. 2006, 290, E1118-E1123
52. Mundil, D.; Beca, S.; Cameron-Vendrig, A.; El-Mounayri, O.; Momen, A.; Backx, P. H.; Husain, M. GLP-1[28-36] exerts direct cardioprotective effects, activating pro-survival kinases and soluble adenylyl cyclase Circulation 2012, 126, 13657
53. Elahi, D.; Angeli, F. S.; Vakilipour, A.; Carlson, O. D.; Tomas, E.; Egan, J. M.; Habener, J. F.; Shannon, R. P. GLP-1(32-36)amide, a novel pentapeptide cleavage product of GLP-1, modulates whole body glucose metabolism in dogs Peptides 2014, 59, 20-24
54. Taing, M. W.; Rose, F. J.; Whitehead, J. P. GLP-1(28-36)amide, the glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly? Drug Des. Dev. Ther. 2014, 8, 677-688
55. Mapelli, C.; Natarajan, S. I.; Meyer, J. P.; Bastos, M. M.; Bernatowicz, M. S.; Lee, V. G.; Pluscec, J.; Riexinger, D. J.; Sieber-McMaster, E. S.; Constantine, K. L.; Smith-Monroy, C. A.; Golla, R.; Ma, Z.; Longhi, D. A.; Shi, D.; Xin, L.; Taylor, J. R.; Koplowitz, B.; Chi, C. L.; Khanna, A.; Robinson, G. W.; Seethala, R.; Antal-Zimanyi, I. A.; Stoffel, R. H.; Han, S.; Whaley, J. M.; Huang, C. S.; Krupinski, J.; Ewing, W. R. Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity J. Med. Chem. 2009, 52, 7788-7799
56. Thornton, K.; Gorenstein, D. G. Structure of glucagon-like peptide(7-36) amide in a dodecylphosphocholine micelle as determined by 2D NMR Biochemistry 1994, 33, 3532-3539
57. Chang, X.; Keller, D.; Bjørn, S.; Led, J. J. Structure and folding of glucagon-like peptide-1-(7-36)-amide in aqueous trifluoroethanol studied by NMR spectroscopy Magn. Reson. Chem. 2001, 39, 477-483
58. Neidigh, J. W.; Fesinmeyer, R. M.; Prickett, K. S.; Andersen, N. H. Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states Biochemistry 2001, 40, 13188-13200
59. Runge, S.; Schimmer, S.; Oschmann, J.; Schiødt, C. B.; Knudsen, S. M.; Jeppesen, C. B.; Madsen, K.; Lau, J.; Thøgersen, H.; Rudolph, R. Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain Biochemistry 2007, 46, 5830-5840
60. Mann, R. J.; Nasr, N. E.; Sinfield, J. K.; Paci, E.; Donnelly, D. The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4 Br. J. Pharmacol. 2010, 160, 1973-1984
61. Underwood, C. R.; Garibay, P.; Knudsen, L. B.; Hastrup, S.; Peters, G. H.; Rudolph, R.; Reedtz-Runge, S. Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor J. Biol. Chem. 2010, 285, 723-730
62. Schröder-Tittmann, K.; Bosse-Doenecke, E.; Reedtz-Runge, S.; Ihling, C.; Sinz, A.; Tittmann, K.; Rudolph, R. Recombinant expression, in vitro refolding, and biophysical characterization of the human glucagon-like peptide-1 receptor Biochemistry 2010, 49, 7956-7965
63. Chen, Q.; Pinon, D. I.; Miller, L. J.; Dong, M. Molecular basis of glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes J. Biol. Chem. 2009, 284, 34135-34144
64. Chen, Q.; Pinon, D. I.; Miller, L. J.; Dong, M. Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor J. Biol. Chem. 2010, 285, 24508-24518
65. Miller, L. J.; Chen, Q.; Lam, P. C.-H.; Pinon, D. I.; Sexton, P. M.; Abagyan, R.; Dong, M. Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling J. Biol. Chem. 2011, 286, 15895-15907
66. Lopez de Maturana, R.; Treece-Birch, J.; Abidi, F.; Findlay, J. B.; Donnelly, D. Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues Protein Pept. Lett. 2004, 11, 15-22
67. Al-Sabah, S.; Donnelly, D. The positive charge at Lys-288 of the glucagon-like peptide-1 (GLP-1) receptor is important for binding the N-terminus of peptide agonists FEBS Lett. 2003, 553, 342-346
68. Lopez de Maturana, R.; Donnelly, D. The glucagon-like peptide-1 receptor binding site for the N-terminus of GLP-1 requires polarity at Asp198 rather than negative charge FEBS Lett. 2002, 530, 244-248
69. Runge, S.; Thogersen, H.; Madsen, K.; Lau, J.; Rudolph, R. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain J. Biol. Chem. 2008, 283, 11340-11347
70. Lopez de Maturana, R.; Willshaw, A.; Kuntzsch, A.; Rudolph, R.; Donnelly, D. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1 J. Biol. Chem. 2003, 278, 10195-10200
71. Murage, E. N.; Schroeder, J. C.; Beinborn, M.; Ahn, J.-M. Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1 Bioorg. Med. Chem. 2008, 16, 10106-10112
72. Ahn, J.-M.; Gitu, P. M.; Medeiros, M.; Swift, J. R.; Trivedi, D.; Hruby, V. J. A new approach to search for the bioactive conformation of glucagon: positional cyclization scanning J. Med. Chem. 2001, 44, 3109-3116
73. Murage, E. N.; Gao, G.; Bisello, A.; Ahn, J.-M. Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges J. Med. Chem. 2010, 53, 6412-6420
74. Kim, M. S.; Polychronakos, C. Immunogenetics of type 1 diabetes Horm. Res. 2005, 64, 180-188
75. Steele, C.; Hagopian, W. A.; Gitelman, S.; Masharani, U.; Cavaghan, M.; Rother, K. I.; Donaldson, D.; Harlan, D. M.; Bluestone, J.; Herold, K. C. Insulin secretion in type 1 diabetes Diabetes 2004, 53, 426-433
76. Kahn, C. R. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes Diabetes 1994, 43, 1066-1084
77. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention: Atlanta, GA, 2011.
78. Mojsov, S. Glucagon-like peptide-1 (GLP-1) and the control of glucose metabolism in mammals and teleost fish Am. Zool. 2000, 40, 246-258
79. Drucker, D. J.; Dritselis, A.; Kirkpatrick, P. Liraglutide Nat. Rev. Drug Discovery 2010, 9, 267-268
80. Mudaliar, S.; Henry, R. R. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function Am. J. Med. 2010, 123, S19-S27
81. Drucker, D. J.; Sherman, S. I.; Gorelick, F. S.; Bergenstal, R. M.; Sherwin, R. S.; Buse, J. B. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits Diabetes Care 2010, 33, 428-433
82. Butler, P. C.; Dry, S.; Elashoff, R. GLP-1-based therapy for diabetes: What you do not know can hurt you Diabetes Care 2010, 33, 453-455
83. Hui, H.; Zhao, X.; Perfetti, R. Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes Diabetes Metab. Res. Rev. 2005, 21, 313-331
84. Lovshin, J. A.; Drucker, D. J. Incretin-based therapies for type 2 diabetes mellitus Nat. Rev. Endocrinol. 2009, 5, 262-269
85. Russell-Jones, D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue Mol. Cell. Endocrinol. 2009, 297, 137-140
86. Drucker, D.; Easley, C.; Kirkpatrick, P. Sitagliptin Nat. Rev. Drug Discovery 2007, 6, 109-110
87. Ahn, J.-M.; Boyle, N. A.; MacDonald, M. T.; Janda, K. D. Peptidomimetics and peptide backbone modifications Mini-Rev. Med. Chem. 2002, 2, 463-473
88. Kim, T. H.; Jiang, H. H.; Lee, S.; Youn, Y. S.; Park, C. W.; Byun, Y.; Chen, X.; Lee, K. C. Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics Bioconjugate Chem. 2011, 22, 625-632
89. Eng, J.; Kleinman, W. A.; Singh, L.; Singh, G.; Raufman, J. P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas J. Biol. Chem. 1992, 267, 7402-7405
90. Thum, A.; Hupe-Sodmann, K.; Goke, R.; Voigt, K.; Goke, B.; McGregor, G. Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4 Exp. Clin. Endocrinol. Diabetes 2002, 110, 113-118
91. Ahren, B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes Nat. Rev. Drug Discovery 2009, 8, 369-385
92. Gallwitz, B. Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus Drug Saf. 2010, 33, 87-100
93. Werner, U.; Haschke, G.; Herling, A. W.; Kramer, W. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes Regul. Pept. 2010, 164, 58-64
94. Christensen, M.; Knop, F. K.; Holst, J. J.; Vilsboll, T. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus IDrugs 2009, 12, 503-513
95. Elbrond, B.; Jakobsen, G.; Larsen, S.; Agerso, H.; Jensen, L. B.; Rolan, P.; Sturis, J.; Hatorp, V.; Zdravkovic, M. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects Diabetes Care 2002, 25, 1398-1404
96. Madsen, K.; Knudsen, L. B.; Agersoe, H.; Nielsen, P. F.; Thøgersen, H.; Wilken, M.; Johansen, N. L. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness J. Med. Chem. 2007, 50, 6126-6132
97. Madsbad, S.; Kielgast, U.; Asmar, M.; Deacon, C.; Torekov, S. S.; Holst, J. J. An overview of once-weekly GLP-1 receptor agonists-available efficacy and safety data and perspectives for the future Diabetes Obes. Metab. 2011, 13, 394-407
98. Kapitza, C.; Heise, T.; Birman, P.; Jallet, K.; Ramis, J.; Balena, R. Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with type 2 diabetes Diabet. Med. 2009, 26, 1156-1164
99. Son, S.; Chae, S. Y.; Kim, C. W.; Choi, Y. G.; Jung, S. Y.; Lee, S.; Lee, K. C. Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives J. Med. Chem. 2009, 52, 6889-6896
100. Denton, E. V.; Craig, C. J.; Pongratz, R. L.; Appelbaum, J. S.; Doerner, A. E.; Narayanan, A.; Shulman, G. I.; Cline, G. W.; Schepartz, A. A β-peptide agonist of the GLP-1 receptor, a class B GPCR Org. Lett. 2013, 15, 5318-5321
101. Bush, M. A.; Matthews, J. E.; De Boever, E. H.; Dobbins, R. L.; Hodge, R. J.; Walker, S. E.; Holland, M. C.; Gutierrez, M.; Stewart, M. W. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects Diabetes Obes. Metab. 2009, 11, 498-505
102. Baggio, L. L.; Huang, Q.; Cao, X.; Drucker, D. J. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis Gastroenterology 2008, 134, 1137-1147
103. Grunberger, G.; Chang, A.; Garcia Soria, G.; Botros, F. T.; Bsharat, R.; Milicevic, Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study Diabetic Med. 2012, 29, 1260-1267
104. Kang, J.; Kim, S.-E.; Choi, I. Y.; Bae, S.; Yoon, Y.-K.; Lee, K. H.; Park, K.-M.; Kwon, S. C.; Son, J. Pharmacokinetic and pharmacodynamic effects of a single dose of the long-acting GLP-1R agonist HM11260C in subjects with type 2 diabetes mellitus. Presented at the 72nd Scientific Sessions American Diabetes Association, Philadelphia, PA, 2012.
105. Diartis presents VRS-859 positive clinical results for type 2 diabetes at 48th EASD annual meeting. http://www.marketwired.com/press-release/diartis-presents-vrs-859-positive-clinical-results-type-2-diabetes-48th-easd-annual-1708016.htm (accessed Aug 21, 2013).
106. Pan, C. Q.; Buxton, J. M.; Yung, S. L.; Tom, I.; Yang, L.; Chen, H.; MacDougall, M.; Bell, A.; Claus, T. H.; Clairmont, K. B.; Whelan, J. P. Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist J. Biol. Chem. 2006, 281, 12506-12515
107. DiMarchi, R. D.; Yang, B.; Ouyang, C. Compounds exhibiting glucagon antagonist and GLP-1 agonist activity. WO2009058734A1, 2009.
108. Day, J. W.; Ottaway, N.; Patterson, J. T.; Gelfanov, V.; Smiley, D.; Gidda, J.; Findeisen, H.; Bruemmer, D.; Drucker, D. J.; Chaudhary, N.; Holland, J.; Hembree, J.; Abplanalp, W.; Grant, E.; Ruehl, J.; Wilson, H.; Kirchner, H.; Lockie, S. H.; Hofmann, S.; Woods, S. C.; Nogueiras, R.; Pfluger, P. T.; Perez-Tilve, D.; DiMarchi, R.; Tschop, M. H. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents Nat. Chem. Biol. 2009, 5, 749-757
109. DiMarchi, R. D.; Tao, M. GIP-based mixed agonists for treatment of metabolic disorders and obesity. WO/2010/011439, 2010.
110. Fosgerau, K.; Skovgaard, M.; Larsen, S. A.; Baek, C. A.; Meier, E.; Groendahl, C.; Bak, H. H. Combination of long-acting insulin with the dual GluGLP-1 agonist ZP2929 causes improved glycemic control without body weight gain in db/db mice Diabetes 2011, 60, A418
111. Transition Therapeutics announces results of clinical study of type 2 diabetes drug candidate TT-401. http://www.transitiontherapeutics.com/media/archive.php# (archived Apr 30, 2013) (accessed Aug 21, 2013).
112. Trevaskis, J. L.; Mack, C. M.; Sun, C.; Soares, C. J.; DSouza, L. J.; Levy, O. E.; Lewis, D. Y.; Jodka, C. M.; Tatarkiewicz, K.; Gedulin, B.; Gupta, S.; Wittmer, C.; Hanley, M.; Forood, B.; Parkes, D. G.; Ghosh, S. S. Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids PLoS One 2013, 8, e78154
113. Vilsbøll, T.; Knop, F. K. Review: DPP IV inhibitors-current evidence and future directions Br. J. Diabetes Vasc. Dis. 2007, 7, 69-74
114. Green, B. D.; Flatt, P. R.; Bailey, C. J. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes Diabetes Vasc. Dis. Res. 2006, 3, 159-165
115. Gupta, R.; Walunj, S. S.; Tokala, R. K.; Parsa, K. V.; Singh, S. K.; Pal, M. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of type 2 diabetes Curr. Drug Targets 2009, 10, 71-87
116. Dicker, D. DPP-4 inhibitors Diabetes Care 2011, 34, S276-S278
117. Murphy, K. G.; Bloom, S. R. Nonpeptidic glucagon-like peptide 1 receptor agonists: A magic bullet for diabetes? Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 689-690
118. Knudsen, L. B.; Kiel, D.; Teng, M.; Behrens, C.; Bhumralkar, D.; Kodra, J. T.; Holst, J. J.; Jeppesen, C. B.; Johnson, M. D.; de Jong, J. C.; Jorgensen, A. S.; Kercher, T.; Kostrowicki, J.; Madsen, P.; Olesen, P. H.; Petersen, J. S.; Poulsen, F.; Sidelmann, U. G.; Sturis, J.; Truesdale, L.; May, J.; Lau, J. Small-molecule agonists for the glucagon-like peptide 1 receptor Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 937-942
119. Irwin, N.; Flatt, P. R.; Patterson, S.; Green, B. D. Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3- N-tert -butylaminoquinoxaline Eur. J. Pharmacol. 2010, 628, 268-273
120. Chen, D.; Liao, J.; Li, N.; Zhou, C.; Liu, Q.; Wang, G.; Zhang, R.; Zhang, S.; Lin, L.; Chen, K.; Xie, X.; Nan, F.; Young, A. A.; Wang, M.-W. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 943-948
121. Sloop, K. W.; Willard, F. S.; Brenner, M. B.; Ficorilli, J.; Valasek, K.; Showalter, A. D.; Farb, T. B.; Cao, J. X.; Cox, A. L.; Michael, M. D.; Gutierrez Sanfeliciano, S. M.; Tebbe, M. J.; Coghlan, M. J. Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets Diabetes 2010, 59, 3099-3107
122. Wootten, D.; Simms, J.; Koole, C.; Woodman, O. L.; Summers, R. J.; Christopoulos, A.; Sexton, P. M. Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids J. Pharmacol. Exp. Ther. 2011, 336, 540-550
123. Gong, Y.-D.; Cheon, H. G.; Lee, T.; Kang, N. S. A novel 3-(8-chloro-6-(trifluoromethyl)imidazo[1,2- a ]pyridine-2-yl)phenyl acetate skeleton and pharmacophore model as glucagon-like peptide 1 receptor agonists Bull. Korean Chem. Soc. 2010, 31, 3760-3764
124. Moon, H.-S.; Yang, J.-S.; Kim, M.-K.; Kim, J.-K.; Lee, J.-Y.; Kang, S.-M.; Kim, H.-D.; Shin, C.-Y.; Cheong, Y.-H.; Yang, E.-K.; Choi, S.-H.; Park, Y.-S.; Kim, E.-J.; Chae, Y.-N.; Cho, E.-J.; Son, M.-H.; Kim, S.-H. Novel quinoxaline derivatives. WO/2011/122815, 2011.
125. Kumarasinghe, I. R.; Murage, E.; Ahn, J.-M. Solution structure of a GLP-1 receptor peptidomimetic agonist, Ac-SH3-GLP-1(22-36)-NH2. In Peptides:Building Bridges, Proceedings of the 22nd American Peptide Symposium; Lebl, M., Ed.; Prompt Scientific Publishing: San Diego, CA, 2011; pp 182-183.
126. Ahn, J.-M.; Han, S.-Y.; Murage, E.; Beinborn, M. Rational design of peptidomimetics for class B GPCRs: potent non-peptide GLP-1 receptor agonists. In Peptides: Chemistry, Structure and Biology, Proceedings of the 20th American Peptide Symposium; Escher, E.; Lubell, W. D.; Valle, S. D., Eds.; Springer: New York, NY, 2009; pp 125-126.
127. Ravindranathan, P.; Lee, T.-K.; Yang, L.; Centenera, M. M.; Butler, L.; Tilley, W. D.; Hsieh, J.-T.; Ahn, J.-M.; Raj, G. V. Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer Nat. Commun. 2013, 4, 1923 10.1038/ncomms2912
128. Ahn, J.-M.; Han, S.-Y. Facile synthesis of benzamides to mimic an a-helix Tetrahedron Lett. 2007, 48, 3543-3547
129. Lee, T.-K.; Ahn, J.-M. Solid-phase synthesis of tris-benzamides as α-helix mimetics ACS Comb. Sci. 2011, 13, 107-111
130. Yang, H. J.; Park, I. S.; Na, K. Biocompatible microspheres based on acetylated polysaccharide prepared from water-in-oil-in-water (W1/O/W2) double-emulsion method for delivery of type II diabetic drug (exenatide) Colloids Surf. Physicochem. Eng. Aspects 2009, 340, 115-120
131. Li, K.; Yu, L.; Liu, X.; Chen, C.; Chen, Q.; Ding, J. A long-acting formulation of a polypeptide drug exenatide in treatment of diabetes using an injectable block copolymer hydrogel Biomaterials 2013, 34, 2834-2842
132. Joabsson, F. C.; Johnsson, M. C.; Tiberg, F. C. GLP-1 analogue formulations. EP1888031A1, 2008.
133. Amiram, M.; Luginbuhl, K. M.; Li, X.; Feinglos, M. N.; Chilkoti, A. Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 2792-2797
134. Decker, S.; Quandt, H.; Kuzma, P. Sustained delivery of exenatide and other polypeptides. EP2303226A2, 2011.
135. Kim, H.; Lee, J.; Kim, T.; Lee, E.; Oh, K.; Lee, D.; Park, E.-S.; Bae, Y.; Lee, K.; Youn, Y. Albumin-coated porous hollow poly(lactic- co -glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes Pharm. Res. 2011, 28, 2008-2019
136. Andersen, C.; Lorenzen, G.; Arent, N.; Thorengaard, B.; Wittorff, H. Compressed chewing gum tablet. US20100255063A1, 2010.
137. Kim, P.-H.; Lee, M.; Kim, S. W. Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model J. Controlled Release 2012, 162, 9-18
138. ADA. Standards of Medical Care in Diabetes-2010. Diabetes Care 2010, 33, S11-S61.
139. Kahn, S. E.; Carr, D. B.; Faulenbach, M. V.; Utzschneider, K. M. An examination of β-cell function measures and their potential use for estimating β-cell mass Diabetes Obes. Metab. 2008, 10, 63-76
140. Gomis, R.; Figuerola, D.; Micalo, T.; Millan, M.; Peig, M. Glycosylated hemoglobin as an index of diabetes mellitus control (authors transl) Med. Clin. 1981, 76, 251-254
141. Berger, B.; Stenstrom, G.; Sundkvist, G. Random C-peptide in the classification of diabetes Scand. J. Clin. Lab. Invest. 2000, 60, 687-693
142. Matveyenko, A. V.; Butler, P. C. Relationship between β-cell mass and diabetes onset Diabetes Obes. Metab. 2008, 10, 23-31
143. Cnop, M.; Welsh, N.; Jonas, J.-C.; Jörns, A.; Lenzen, S.; Eizirik, D. L. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities Diabetes 2005, 54 (Suppl. 2) S97-107
144. Souza, F.; Freeby, M.; Hultman, K.; Simpson, N.; Herron, A.; Witkowsky, P.; Liu, E.; Maffei, A.; Harris, P. E. Current progress in non-invasive imaging of beta cell mass of the endocrine pancreas Curr. Med. Chem. 2006, 13, 2761-2773
145. Halban, P. A. Cellular sources of new pancreatic beta cells and therapeutic implications for regenerative medicine Nat. Cell Biol. 2004, 6, 1021-1025
146. Ueberberg, S.; Meier, J. J.; Waengler, C.; Schechinger, W.; Dietrich, J. W.; Tannapfel, A.; Schmitz, I.; Schirrmacher, R.; Köller, M.; Klein, H. H.; Schneider, S. Generation of novel single-chain antibodies by phage-display technology to direct imaging agents highly selective to pancreatic β- or α-cells in vivo Diabetes 2009, 58, 2324-2334
147. Moore, A. Advances in beta-cell imaging Eur. J. Radiol. 2009, 70, 254-257
148. Saudek, F.; Brogren, C. H.; Manohar, S. Imaging the beta-cell mass: why and how Rev. Diabetic Stud. 2008, 5, 6-12
149. Ichise, M.; Harris, P. E. Imaging of β-cell mass and function J. Nucl. Med. 2010, 51, 1001-1004
150. Malaisse, W. J.; Louchami, K.; Sener, A. Noninvasive imaging of pancreatic beta cells Nat. Rev. Endocrinol. 2009, 5, 394-400
151. Shiue, C. Y.; Schmitz, A.; Schirrmacher, R.; Shiue, G. G.; Alavi, A. Potential approaches for beta cell imaging with PET and SPECT Curr. Med. Chem.: Immunol., Endocr. Metab. Agents 2004, 4, 271-280
152. Schneider, S. Efforts to develop methods for in vivo evaluation of the native β-cell mass Diabetes Obes. Metab. 2008, 10, 109-118
153. Murthy, R.; Harris, P.; Simpson, N.; Van Heertum, R.; Leibel, R.; Mann, J.; Parsey, R. Whole body [11C]-dihydrotetrabenazine imaging of baboons: biodistribution and human radiation dosimetry estimates Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 790-797
154. Kung, M. P.; Hou, C.; Lieberman, B. P.; Oya, S.; Ponde, D. E.; Blankemeyer, E.; Skovronsky, D.; Kilbourn, M. R.; Kung, H. F. In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus J. Nucl. Med. 2008, 49, 1171-1176
155. Harris, P.; Ferrara, C.; Barba, P.; Polito, T.; Freeby, M.; Maffei, A. VMAT2 gene expression and function as it applies to imaging β-cell mass J. Mol. Med. 2008, 86, 5-16
156. Goland, R.; Freeby, M.; Parsey, R.; Saisho, Y.; Kumar, D.; Simpson, N.; Hirsch, J.; Prince, M.; Maffei, A.; Mann, J. J.; Butler, P. C.; Van Heertum, R.; Leibel, R. L.; Ichise, M.; Harris, P. E. 11C-Dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls J. Nucl. Med. 2009, 50, 382-389
157. Tornehave, D.; Kristensen, P.; Romer, J.; Knudsen, L. B.; Heller, R. S. Expression of the GLP-1 receptor in mouse, rat, and human pancreas J. Histochem. Cytochem. 2008, 56, 841-51
158. Connolly, B.; Vanko, A.; McQuade, P.; Guenther, I.; Meng, X.; Rubins, D.; Waterhouse, R.; Hargreaves, R.; Sur, C.; Hostetler, E. Ex vivo imaging of pancreatic beta cells using a radiolabeled GLP-1 receptor agonist Mol. Imaging Biol. 2012, 14, 79-87
159. Selvaraju, R. K.; Velikyan, I.; Johansson, L.; Wu, Z.; Todorov, I.; Shively, J.; Kandeel, F.; Korsgren, O.; Eriksson, O. In vivo imaging of the glucagon like peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4 J. Nucl. Med. 2013, 54, 1458-1463
160. Reiner, T.; Kohler, R. H.; Liew, C. W.; Hill, J. A.; Gaglia, J.; Kulkarni, R. N.; Weissleder, R. Near-infrared fluorescent probe for imaging of pancreatic β cells Bioconjugate Chem. 2010, 21, 1362-1368
161. Brom, M.; Oyen, W. J.; Joosten, L.; Gotthardt, M.; Boerman, O. C. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 1345-1355
162. Wild, D.; Béhé, M.; Wicki, A.; Storch, D.; Waser, B.; Gotthardt, M.; Keil, B.; Christofori, G.; Reubi, J. C.; Mäcke, H. R. [Lys40(Ahx-DTPA-111In)NH2]Exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting J. Nucl. Med. 2006, 47, 2025-2033
163. Gotthardt, M.; Lalyko, G.; van Eerd-Vismale, J.; Keil, B.; Schurrat, T.; Hower, M.; Laverman, P.; Behr, T. M.; Boerman, O. C.; Göke, B.; Béhé, M. A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents Regul. Pept. 2006, 137, 162-167
164. Wild, D.; Wicki, A.; Mansi, R.; Béhé, M.; Keil, B.; Bernhardt, P.; Christofori, G.; Ell, P. J.; Mäcke, H. R. Exendin-4-based radiopharmaceuticals for glucagon like peptide-1 receptor PET/CT and SPECT/CT J. Nucl. Med. 2010, 51, 1059-1067
165. Wu, Z.; Todorov, I.; Li, L.; Bading, J. R.; Li, Z.; Nair, I.; Ishiyama, K.; Colcher, D.; Conti, P. E.; Fraser, S. E.; Shively, J. E.; Kandeel, F. In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-exendin-4 by targeting GLP-1 receptor Bioconjugate Chem. 2011, 22, 1587-1594
166. Ahn, J.-M.; Murage, E. N.; Lo, S.-T.; Lin, M.; Sun, X. Highly constrained GLP-1 analogues as non-invasive PET imaging agents for the assessment of pancreatic beta-cell mass. In Peptides:Building Bridges, Proceedings of the 22nd American Peptide Symposium; Lebl, M., Ed.; Prompt Scientific Publishing: San Diego, CA, 2011; pp 220-221.
167. Ahn, J.-M.; Sun, X. Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells. WO2010118034A2, 2010.
168. Wicki, A.; Wild, D.; Storch, D.; Seemayer, C.; Gotthardt, M.; Behe, M.; Kneifel, S.; Mihatsch, M. J.; Reubi, J.-C.; Mäcke, H. R.; Christofori, G. [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma Clin. Cancer Res. 2007, 13, 3696-3705
169. Pattou, F.; Kerr-Conte, J.; Wild, D. GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle N. Engl. J. Med. 2010, 363, 1289-1290
170. Reiner, T.; Thurber, G.; Gaglia, J.; Vinegoni, C.; Liew, C. W.; Upadhyay, R.; Kohler, R. H.; Li, L.; Kulkarni, R. N.; Benoist, C.; Mathis, D.; Weissleder, R. Accurate measurement of pancreatic islet β-cell mass using a second-generation fluorescent exendin-4 analog Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 12815-12820
171. Mukai, E.; Toyoda, K.; Kimura, H.; Kawashima, H.; Fujimoto, H.; Ueda, M.; Temma, T.; Hirao, K.; Nagakawa, K.; Saji, H.; Inagaki, N. GLP-1 receptor antagonist as a potential probe for pancreatic beta-cell imaging Biochem. Biophys. Res. Commun. 2009, 389, 523-526
172. Gao, H.; Niu, G.; Yang, M.; Quan, Q.; Ma, Y.; Murage, E. N.; Ahn, J.-M.; Kiesewetter, D. O.; Chen, X. PET of insulinoma using 18F-FBEM-EM3106B, a new GLP-1 analogue Mol. Pharmaceutics 2011, 8, 1775-1782
173. Manandhar, B.; Lo, S.-T.; Murage, E.; Lin, M.; Sun, X.; Ahn, J.-M. Targeting GLP-1R for non-invasive assessment of pancreatic beta-cell mass. In Peptides across the Pacific, Proceedings of the 23rd American Peptide Symposium; Lebl, M., Ed. Prompt Scientific Publishing: San Diego, CA, 2013; pp 172-173.
174. Silvers, W.; Ramezani, S.; Lo, S.-T.; Kumar, A.; Ahn, J.-M.; Manandhar, B.; Lingvay, I.; Anderson, J. A.; Sun, X.; Öz, O. K. A pilot study on glucagon-like peptide 1 receptor (GLP-1R) targeted PET imaging of beta-cell mass (BCM) in Ossawbaw mini-pigs. Presented at the World Molecular Imaging Congress, Sep 19, 2013; Presentation LBAP 022.